Synonyms: CYT-387 | CYT387 | GS-0387 | GS0387 | Ojjaara® | Omjjara®
momelotinib is an approved drug (FDA (2023), Japan PMDA & EMA (2024))
Compound class:
Synthetic organic
Comment: Momelotinib (a.k.a. CYT387 and GS0387) is an oral Janus kinase inhibitor (ATP-competitive)/activin A receptor type 1 (ACVR1) inhibitor [3]. Inhibition of JAK1/2 is proposed to improve constitutional symptoms (fatigue, night sweats, bone pain) and splenomegaly in myelofibrosis patients. Momelotinib also inhibits the bone morphogenetic protein kinase ACVR1, a mechanism that improves iron homeostasis and erythropoiesis via down-regulation of hepcidin [1], and which may provide benefit to combat anaemia/thrombocytopenia in myelofibrosis [5].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Selectivity at enzymes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|